Navacaprant information

Navacaprant
Clinical data
Other names	BTRX-140; CYM-53093; NMRA-140; NMRA-335140
Identifiers
	IUPAC name 1-[6-ethyl-8-fluoro-4-methyl-3-(3-methyl-1,2,4-oxadiazol-5-yl)quinolin-2-yl]-N-(oxan-4-yl)piperidin-4-amine;
CAS Number	2244614-14-8;
PubChem CID	137434175;
ChemSpider	78316413;
UNII	XK5ILZ28KI;
KEGG	D12869;
Chemical and physical data
Formula	C25H32FN5O2
Molar mass	453.562 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCC1=CC2=C(C(=C(N=C2C(=C1)F)N3CCC(CC3)NC4CCOCC4)C5=NC(=NO5)C)C;
	InChI InChI=1S/C25H32FN5O2/c1-4-17-13-20-15(2)22(25-27-16(3)30-33-25)24(29-23(20)21(26)14-17)31-9-5-18(6-10-31)28-19-7-11-32-12-8-19/h13-14,18-19,28H,4-12H2,1-3H3; Key:CQOJHAJWCDJEAT-UHFFFAOYSA-N;

Navacaprant (developmental code names include BTRX-335140, BTRX-140, CYM-53093, NMRA-335140, and NMRA-140), is a selective κ-opioid receptor antagonist which is under development for the treatment of major depressive disorder.^[1]^[2]^[3] As of December 2023, navacaprant is in phase 3 clinical trials for this indication.^[4]

^ "BlackThorn Therapeutics Advances Phase 2 Clinical Development for Selective KOR Antagonist, BTRX-140, in Neuropsychiatric Disorders". BlackThorn Therapeutics. Archived from the original on 2020-01-25. Retrieved 2020-01-25.
^ "BTRX 335140 - AdisInsight". adisinsight.springer.com. Retrieved 2020-01-25.
^ Guerrero M, Urbano M, Kim EK, Gamo AM, Riley S, Abgaryan L, Leaf N, Van Orden LJ, Brown SJ, Xie JY, Porreca F, Cameron MD, Rosen H, Roberts E (February 2019). "Design and Synthesis of a Novel and Selective Kappa Opioid Receptor (KOR) Antagonist (BTRX-335140)". J. Med. Chem. 62 (4): 1761–1780. doi:10.1021/acs.jmedchem.8b01679. PMC 6395531. PMID 30707578.
^ Neumora Therapeutics, Inc. (2024-02-20). A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder (Report). clinicaltrials.gov.

[BlackThornRx-1] "BlackThorn Therapeutics Advances Phase 2 Clinical Development for Selective KOR Antagonist, BTRX-140, in Neuropsychiatric Disorders". BlackThorn Therapeutics. Archived from the original on 2020-01-25. Retrieved 2020-01-25.

[AdisInsight-2] "BTRX 335140 - AdisInsight". adisinsight.springer.com. Retrieved 2020-01-25.

[pmid30707578-3] Guerrero M, Urbano M, Kim EK, Gamo AM, Riley S, Abgaryan L, Leaf N, Van Orden LJ, Brown SJ, Xie JY, Porreca F, Cameron MD, Rosen H, Roberts E (February 2019). "Design and Synthesis of a Novel and Selective Kappa Opioid Receptor (KOR) Antagonist (BTRX-335140)". J. Med. Chem. 62 (4): 1761–1780. doi:10.1021/acs.jmedchem.8b01679. PMC 6395531. PMID 30707578.

[4] Neumora Therapeutics, Inc. (2024-02-20). A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder (Report). clinicaltrials.gov.

Navacaprant information

and 28 Related for: Navacaprant information

Navacaprant

Ketamine

Fentanyl

Kava

Papaver somniferum

Oxycodone

Hydrocodone

Dextromethorphan

Tramadol

Desomorphine

Cannabidiol

Methadone

Loperamide

Laudanum

Phenylalanine

Menthol

Pethidine

Atomoxetine

Hydromorphone

Salvia divinorum

Buprenorphine

Codeine

Naltrexone

Mitragyna speciosa

Opium

Morphine

Phencyclidine

Opioid